Last week, the Home Secretary announced that, with all party agreement, the Data Retention and Investigatory Powers Bill – (DRIP for short) – would be introduced into Parliament. Much of that is covered in the previous post of 10th July. Since then, criticism has mounted in relation to the late introduction of the Bill prior …
Continue reading “Guest post: DRIP – a torrent of mass surveillance seems more likely”
Lady Butler Sloss, a former and eminent senior judge, with significant experience through a child abuse inquiry (Cleveland) of matters of child protection has been appointed to lead an independent inquiry into historical child abuse. Interestingly, she relinquished the Diana inquest when forced to have a jury trial. The Telegraph story at the time reported: ‘These …
Continue reading “Guest post: A few thoughts on the Butler Sloss controversy”
Introducing the annual report for the Serious Fraud Office (SFO) in the last financial year David Green, CB QC, director of the SFO had this to say: ‘Since I took up post in April 2012, we have sharpened the strategic focus of the SFO on the casework for which the Roskill model was designed and intended. This …
Dennis Kerrison and Miltiades Papachristos were found guilty [on Wednesday 18 June] at Southwark Crown Court of conspiracy to commit corruption. In a nutshell, that they gave or agreed to give corrupt payments to public officials and other agents of the Government of Indonesia as inducements to secure, or as rewards for having secured, contracts …
In front of the Commons Business committee last week, Ian Read, chairman and chief executive of Pfizer, made two points in relation to Pfizer’s commitments, assuming it were to succeed in acquiring the Anglo-Swedish drug manufacturer AstraZeneca.
On April 28, Pfizer announced a possible offer to buy AstraZeneca, presumably having thought an announcement was required by rule 2.2 of the Takeover Code. The result is that, under the relatively new ‘put up or shut up’ rule now embodied in rule 2.5 of the Code, Pfizer has until 5 o’clock on May 26 …
Continue reading “Guest post: Pfizer’s bid for AstraZeneca – what can the government do?”
Loyal readers of Adam Smith, Esq. know that we think there’s much that can be learned for Law Land from other industries. Today’s column is in that vein, and our texts for today come from The New York Times and Above the Law.
At Friday’s ‘Grayling Day’ demonstration in London, chairman of the Criminal Bar Association Nigel Lithman QC told the audience that ‘an indispensable part of our democracy is the criminal justice system. It’s taken centuries to build; it is taking this government a blink of an eye to demolish.’
‘Cooperation, cooperation, cooperation’ is the Serious Fraud Office (SFO)’s message to corporates looking to enter into new US-style plea bargains available [this week]. From [today, 24 February] the Americanisation of corporate crime in England continues. Businesses (but not individuals) will be able to enter into Deferred Prosecution Agreements (DPAs) with the UK taking a leaf …
Winning a new client for the firm—there’s little that can match that for excitement, sense of accomplishment and visible contribution to the firm. More so if the client is big or prestigious. A pitch is often a hard-fought battle against many worthy foes. There are numerable, maddening unknowns in pitching a new client: which lawyers …
Continue reading “Guest post – Client retention: give credit where credit’s due”
